Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
11 Abril 2024 - 7:05AM
Tevogen Bio Holdings (Tevogen) (Nasdaq: TVGN), is a
clinical-stage specialty immunotherapy biotech pioneer developing
off-the-shelf, genetically unmodified T cell therapeutics in
virology, oncology, and neurology. Neal Flomenberg, MD, Tevogen’s
Chief Scientific Officer, explains the company’s oncology pipeline
strategy.
“CTLs can be used for cancer treatments in several ways. Certain
cancers are virally driven and can be targeted very similarly to
targeting other viral infections. Our overwhelmingly positive
experience with TVGN 489 gives us confidence that such an approach
would succeed.
For example, virtually all cases of cervical cancer are caused
by Human Papilloma Virus (HPV). After being infected by HPV, the
virus remains in the cells before and after transformation to
cancer. The virus can be targeted by CTLs before cancer
transformation as a preventative step or after transformation as
part of treatment. This approach could spare many women from
surgical procedures and, in other cases, reduce the size and scope
of a surgery to something more modest. In advanced cases, CTLs
could be combined with other treatments.”
Dr. Flomenberg goes on to explain, “Some cancers that are not
triggered by viruses can be targeted in other ways. The simplest
next step would be to selectively coat the tumor cells with viral
targets and use anti-viral CTLs to then eliminate them. Additional
approaches are in development to take this approach even further in
the treatment of other cancers.”
About Tevogen
Tevogen is a clinical-stage specialty immunotherapy company
harnessing one of nature’s most powerful immunological weapons,
CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically
unmodified precision T cell therapies for the treatment of
infectious diseases, cancers, and neurological disorders, aiming to
address the significant unmet needs of large patient populations.
Tevogen Leadership believes that sustainability and commercial
success in the current era of healthcare rely on ensuring patient
accessibility through advanced science and innovative business
models. Tevogen has reported positive safety data from its
proof-of-concept clinical trial, and its key intellectual property
assets are wholly owned by the company, not subject to any
third-party licensing agreements. These assets include three
granted patents and twelve pending patents, two of which are
related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry
leaders and distinguished scientists with drug development and
global product launch experience. Tevogen’s leadership believes
that accessible personalized therapeutics are the next frontier of
medicine, and that disruptive business models are required to
sustain medical innovation.
Forward Looking Statements
This press release contains certain forward-looking statements,
including without limitation statements relating to: expectations
regarding the healthcare and biopharmaceutical industries;
Tevogen’s development of, the potential benefits of, and patient
access to its product candidates for the treatment of infectious
diseases, cancer and neurological disorders, including TVGN 489 for
the treatment of COVID-19 and Long COVID; Tevogen’s ability to
develop additional product candidates, including through use of
Tevogen’s ExacTcell platform; the anticipated benefits of
ExacTcell; expectations regarding Tevogen’s future clinical trials;
Tevogen’s manufacturing plans; and Tevogen’s ability to generate
revenue in the future. Forward-looking statements can sometimes be
identified by words such as “may,” “could,” “would,” “expect,”
“possible,” “potential,” “goal,” “opportunity,” “project,”
“believe,” “future,” and similar words and expressions or their
opposites. These statements are based on management’s expectations,
assumptions, estimates, projections and beliefs as of the date of
this presentation and are subject to a number of factors that
involve known and unknown risks, delays, uncertainties and other
factors not under the company’s control that may cause actual
results, performance or achievements of the company to be
materially different from the results, performance or other
expectations expressed or implied by these forward-looking
statements.
These factors include, but are not limited to: (i) the effect of
the recent business combination with Semper Paratus Acquisition
Corporation (the “Business Combination”) on Tevogen’s business
relationships, operating results, and business generally; (ii) the
outcome of any legal proceedings that may be instituted against
Tevogen related to the Business Combination; (iii) changes in the
markets in which Tevogen competes, including with respect to its
competitive landscape, technology evolution, or regulatory changes;
(iv) changes in domestic and global general economic conditions;
(v) the risk that Tevogen may not be able to execute its growth
strategies or may experience difficulties in managing its growth
and expanding operations; (vi) the risk that Tevogen may not be
able to develop and maintain effective internal controls; (vii)
costs related to the Business Combination and the failure to
realize anticipated benefits of the Business Combination; (viii)
the failure to achieve Tevogen’s commercialization and development
plans, and identify and realize additional opportunities, which may
be affected by, among other things, competition, the ability of
Tevogen to grow and manage growth economically and hire and retain
key employees; (ix) the risk that Tevogen may fail to keep pace
with rapid technological developments to provide new and innovative
products and services or make substantial investments in
unsuccessful new products and services; (x) the ability to develop,
license or acquire new therapeutics; (xi) that Tevogen will need to
raise additional capital to execute its business plan, which may
not be available on acceptable terms or at all; (xii) the risk of
regulatory lawsuits or proceedings relating to Tevogen’s business;
(xiii) uncertainties inherent in the execution, cost, and
completion of preclinical studies and clinical trials; (xiv) risks
related to regulatory review, and approval and commercial
development; (xv) risks associated with intellectual property
protection; (xvi) Tevogen’s limited operating history; and (xvii)
those factors discussed in Tevogen’s filings with the SEC and that
that are contained in the Proxy Statement/Prospectus relating to
the Business Combination.
You should not place undue reliance on forward-looking
statements, which speak only as of the date they are made. Tevogen
undertakes no obligation to update any forward-looking statements,
except as required by applicable law.
Contacts
Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Tevogen Bio (NASDAQ:TVGN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Tevogen Bio (NASDAQ:TVGN)
Gráfica de Acción Histórica
De May 2023 a May 2024